World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://wjon.elmerpub.com

Original Article

Volume 16, Number 4, August 2025, pages 331-341

Efficacy of Infliximab Versus Vedolizumab in the Management of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review and Meta-Analysis

Figures

Figure 1.
Figure 1. PRISMA flowchart. PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Figure 2.
Figure 2. Risk of bias assessment of selected studies.
Figure 3.
Figure 3. Recurrence of colitis: vedolizumab vs. infliximab. OR: odds ratio; CI: confidence interval.
Figure 4.
Figure 4. Median dose of steroid exposure: vedolizumab vs. infliximab. MD: mean difference; CI: confidence interval.
Figure 5.
Figure 5. Remission of colitis: vedolizumab vs. infliximab. OR: odds ratio; CI: confidence interval.
Figure 6.
Figure 6. Difference in mean SIT doses (vedolizumab vs. infliximab). SD: standard deviation; MD: mean difference; CI: confidence interval.
Figure 7.
Figure 7. Mean doses of vedolizumab. SD: standard deviation; MRAW: raw mean score; CI: confidence interval.
Figure 8.
Figure 8. Mean doses of infliximab. SIT: selective immunosuppressive therapy; SD: standard deviation; CI: confidence interval; MRAW: raw mean score.

Tables

Table 1. Characteristics of Studies Included
 
StudyMale sex (n)Median age (years)White race (n)Total patients who received SIT (n)YearCountryStudy designVDZ only (n)IFX only (n)IFX f/b VDZ (n)VDZ f/b IFX (n)Types of cancer (n)
RC: retrospective cohort; N/A: not available; VDZ: vedolizumab; IFX: infliximab; f/b: followed by; GU: genitourinary; GI: gastrointestinal; RCC: renal cell carcinoma.
Zou et al, 2021 [18]118641691842021USARC6294280Melanoma: 54
GU cancer: 49
Lung cancer: 26
Others: 27
Stage 3: 26
Stage 4: 130
Abu-Sbeih et al, 2019 [19]666076842019USARC324642Melanoma: 40
GU cancer: 28
Thoracic, head and neck cancer: 11
Stage 4: 72
Badran et al, 2023 [20]4261.3N/A772023USARC443300Melanoma: 35
GU cancer: 14
Lung/head/neck cancer: 15
GI cancer: 6
Endocrine: 1
Other: 6
Stage: N/A
Machado et al, 2023 [21]105631391562023USARC5981160Melanoma: 70
GU cancer: 53
Thoracic/head and neck cancer: 20
GI cancer: 6
Hematological: 3
Other: 5
Stage 3: 22
Stage 4: 134
Joseph et al, 2024 [22]296555552024USARC223300Melanoma: 28
Non-melanoma: 27
Metastatic cancer: 29
Metastatic: 29
Abu-Sbeih et al, 2018 [23]2063N/A282018USARC19990Melanoma: 7
RCC: 4
Prostate carcinoma: 4
Urothelial cancer: 3
Other solid tumors: 10
Stage 3: 6
Stage 4: 22

 

Table 2. Number of Patients Receiving Particular ICI and Number of Doses of SIT Administered
 
StudyOutcomesICI typeSIT
Anti-CTLA-4 (n)Combined (n)Anti PD (L)-1 (n)VDZ (n)IFX (n)
aCTLA-4 alone or in combination. ICI: immune checkpoint inhibitor; CTLA-4: cytotoxic T-lymphocyte-associated antigen 4; VDZ: vedolizumab; IFX: infliximab; SIT: selective immunosuppressive therapy; SD: standard deviation; IQR: interquartile range.
Zou et al, 2021 [18]Remission, recurrence, median duration of steroid exposure, mean doses of SIT2355783 (SD: 2)2 (SD: 1)
Abu-Sbeih et al, 2019 [19]Recurrence, mean doses of SIT2130333 (IQR: 1 - 6)1 (IQR: 1 - 3)
Badran et al, 2023 [20]Recurrence34232N/AN/A
Machado et al, 2023 [21]Median duration of steroid exposure, mean doses of SIT2662683 (IQR: 2 - 4)1 (IQR: 1 - 2)
Joseph et al, 2024 [22]Recurrence, median duration of steroid exposure, mean doses of SIT20a351 (IQR: 1 - 2)1 (IQR: 1 - 2)
Abu-Sbeih et al, 2018 [23]Remission, mean doses of SIT88123 (IQR: 1 - 4)2 (IQR: 1 - 3)